Abstract | BACKGROUND: METHODS: RESULTS: The median follow-up was 29 months. Twenty-six patients dropped out (13 in the isosorbide group) because of poor compliance or complications unrelated to treatment. Eighteen patients died (9 in the isosorbide-treated group), 6 due to bleeding. The 1- and 2-year actuarial percentages of patients free of bleeding was 90.8% and 82.2% in the isosorbide-5-mononitrate--and 93.9% and 85.8% in the propranolol-treated groups, respectively (P = NS). These values are higher than those expected from the North Italian Endoscopic Club predicting scores. There were few major side effects in either group. The 2-year survival rate did not differ between the two groups (82.2% vs. 85.4%). CONCLUSIONS:
|
Authors | M Angelico, L Carli, C Piat, S Gentile, V Rinaldi, E Bologna, L Capocaccia |
Journal | Gastroenterology
(Gastroenterology)
Vol. 104
Issue 5
Pg. 1460-5
(May 1993)
ISSN: 0016-5085 [Print] United States |
PMID | 8482456
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Propranolol
- Isosorbide Dinitrate
- isosorbide-5-mononitrate
|
Topics |
- Aged
- Digestive System
(pathology)
- Endoscopy
- Female
- Gastrointestinal Hemorrhage
(etiology, prevention & control)
- Humans
- Isosorbide Dinitrate
(adverse effects, analogs & derivatives, therapeutic use)
- Liver Cirrhosis
(complications, drug therapy, mortality)
- Male
- Middle Aged
- Patient Dropouts
- Personnel Selection
- Propranolol
(adverse effects, therapeutic use)
- Prospective Studies
|